News
Milestones, investments and media coverage of August Global Partners, newest first.
AI Benefits GPs, but Some Perks May Be Overstated
DealStreetAsia reports on "The AI test for GPs" panel at its Asia PE-VC Summit 2026, featuring Founding Partner & CEO Dr Basil Lui alongside Neuberger, TPG Asia and Collyer Capital. Dr Lui noted that AI can lower barriers to entry and pressure valuation multiples, so durable moats in manufacturing, distribution, customer relationships and proprietary networks still matter, and that investment committees must keep "the human in the loop" for final decisions.
AGP Partner Davian Sim Speaks at SuperReturn Asia 2026
At SuperReturn Asia 2026 in Singapore, Partner Davian Sim joined the panel "Sourcing talent: finding the right leader for your PortCo" with Wavemaker Partners and Novo Holdings Asia on 1 October. He discussed founder-to-CEO transitions at growth stage, the leadership traits that carry across stages, and why the CFO bench matters. His perspective is in AGP's Opinions section.
AGP Partners Speak at DealStreetAsia's Asia PE-VC Summit 2026
At DealStreetAsia's 11th Asia PE-VC Summit in Singapore, Partner Davian Sim joined the opening breakfast panel hosted by Vistra Fund Solutions, "When Global Capital Fractures: Opportunity and Friction in APAC Private Markets", on 23 September. On 24 September, Founding Partner & CEO Dr Basil Lui spoke on "The AI test for GPs: Underwriting disruption, transforming portfolios and proving value to LPs" alongside Neuberger and TPG. Both have since published their perspectives in AGP's Opinions section.
Shape Memory Medical Secures $10M Financing Led by AGP to Advance Aortic Clinical Programs
AGP leads a $10M convertible note financing in Shape Memory Medical, a California-based medical device company developing proprietary shape memory polymer technology for endovascular embolization, with participation from Taiwania Capital and support from HEAL Venture Lab. Proceeds will fund continued clinical development of the company's aortic portfolio, including patient follow-up in the AAA-SHAPE Pivotal Trial (IMPEDE-FX RapidFill®) and advancement of the FLAGSHIP first-in-human feasibility trial (False Lumen Embolization System for aortic dissection). AGP Partner Davian Sim is quoted on the platform's potential as the company reaches an inflection point across its clinical programs.
Ambiq Micro's SGX Secondary Listing a 'Reflection of Commitment'
AGP portfolio company Ambiq Micro announces a secondary listing on the Singapore Exchange, complementing its existing NYSE listing. CEO Fumihide Esaka describes the move as a "reflection of commitment" to Singapore and the Asia-Pacific region, alongside a multi-year R&D programme in Singapore for Ambiq's sub-threshold power optimised (Spot) platform. The article notes August Global Partners among Ambiq's investors.
Singapore's Care Tech Race Heats Up as City-State Ages Rapidly
Nikkei Asia features Singapore's rapidly growing eldercare technology ecosystem as the city-state becomes a super-aged society in 2026. AGP CEO Dr Basil Lui is quoted on what eldercare tech firms need to demonstrate to attract institutional private capital — "clinical and economic efficacy, with hard diagnostic data that actively reduces overall hospital readmissions or long-term care costs, along with cross-border scalability of solutions across the region."
Gene Solutions' SPOT-MAS 10 Receives FDA Breakthrough Device Designation
AGP portfolio company Gene Solutions receives FDA Breakthrough Device Designation for SPOT-MAS 10, its 10-cancer early detection blood test based on cell-free DNA methylation analysis.
Ambiq Accelerates Sales Growth on Edge AI Demand
AGP portfolio company Ambiq accelerates sales growth as edge AI demand drives adoption of its sub-threshold power optimised chips across smart devices and wearables.
AGP Featured in DealStreetAsia's SE Asia PE Funds H2 2025 Review
August Global Partners is featured in DealStreetAsia's semi-annual review of Southeast Asia's private equity fund landscape for H2 2025.
AGP Recognised as Tech@SG Pioneer / Recognised Investor
August Global Partners is recognised as a Tech@SG Pioneer / Recognised Investor by Singapore's Economic Development Board.
UltraGreen.ai IPO
AGP portfolio company UltraGreen.ai completes its IPO, marking another listing for the AGPCGF portfolio.
AGPHCF Closes at $150M
The AGP Healthcare Fund (AGPHCF) formally closes at $150M, dedicated to the Living Better, Aging Better theme across precision medicine, diagnostics, medical technology, digital health, and healthcare services.
65 Equity Partners UltraGreen.ai
65 Equity Partners and other investors participate in UltraGreen.ai financing alongside AGP.
Singapore's August Global Partners Invests in Gene Solutions
AGP invests in Vietnam's leading genomic testing company Gene Solutions through a proprietary funding round.
Basil Lui at PE-VC Summit
AGP Founding Partner and CEO Dr Basil Lui speaks at DealStreetAsia's PE-VC Summit on Southeast Asia healthcare investment themes.
Ex-EDBI Chief Launches $250M Firm
August Global Partners launches under founding partners Chu Swee Yeok PBM (former EDBI CEO) and Dr Basil Lui, with an initial platform target of ~US$250M across two inaugural funds.
Machine-readable versions: llms.txt · llms-full.txt · agp.md · news.json · opinions.json · team.json · Home
August Global Partners Pte. Ltd. is a Capital Markets Services Licensee for fund management, regulated by the Monetary Authority of Singapore (MAS Financial Institutions Directory). Nothing on this site is an offer of securities or investment advice. See the legal disclaimer.